LGVN - Longeveron rises ~20% co to present Alzheimer's trial abstract at leading conference
- Longeveron ( NASDAQ: LGVN ) stock gained as much as 19.9% to $7.3 in Thursday trading, after the biotech said an abstract on its phase 2a trial for its Alzheimer's Disease (AD) cell-based therapy Lomecel-B was accepted for a poster presentation at a leading AD conference.
- LGVN said the poster titled "The Effects of Multiple Doses of Lomecel-B, Longeveron’s Cell-based Therapy, on Alzheimer’s Disease: Study Design and Rationale of this Phase 2a Multi- center Clinical trial" was accepted at the Alzheimer’s Association International Conference.
- The conference will be held from July 31 to Aug. 4 in California.
- LGVN said enrollment is currently ongoing in the mid-stage trial.
- LGVN stock was last up 8.7% at $6.62.
- Most mid- and late-stage data readouts over the last few years for Alzheimer's therapies have met with failure , with almost all of the candidates targeting the beta-amyloid plaque in the brain that is thought to play a role in the memory-robbing disease.
For further details see:
Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference